AstraZeneca Loses U.S. Patent Case
A Missouri judge handed European drug giant AstraZeneca (AZN) a defeat in a case involving two patents for the hypertension drug Toprol-XL, finding both invalid and unenforceable.
AstraZeneca said it will appeal the ruling. Both patents are due to expire in September 2007.
The drug, in addition to treating hypertension, is also used for the long-term treatment of angina pectoris and certain types of heart failure. Andrx believes it may be entitled to 180 days of market exclusivity on the 50 mg strength of generic Toprol-XL. The drug had total U.S. sales of $1.29 billion last year, AstraZeneca said.Shares of Andrx were rising 4.9% to $17.40 in premarket trading. AstraZeneca's American depositary shares were losing 3.8% to $47.48.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV